[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626588":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":28,"locations":34,"responsibleParty":54,"collaborators":11,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":11,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":37,"whyStopped":11,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Hudson Biotech","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A: GHK-Cu Gel (0.1% w\u002Fw) applied once daily to the assigned wound for 14 days + standard non-adh","EXPERIMENTAL",null,[13,14],"Drug: GHK-Cu Gel (Copper(II)-peptide complex)","Drug: vehicle Gel (placebo comparator)",{"label":16,"type":10,"description":11,"interventionNames":17},"Arm B: Vehicle Gel applied once daily to the assigned wound for 14 days + standard non-adherent dres",[13,14],[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","GHK-Cu Gel (Copper(II)-peptide complex)","topical gel, 0.1% w\u002Fw; apply a thin film (approx. 0.5 g) once daily for 14 days.",[9,16],{"type":20,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"vehicle Gel (placebo comparator)","ehicle Gel (placebo comparator",[9,16],[29],{"name":30,"role":31,"phone":32,"phoneExt":11,"email":33},"Seni S Lu, Phd","CONTACT","+86 13076790030","Seni-Lu@beijing-biotech.com",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Peking University Shenzhen Hospital","RECRUITING","Shenzhen","Guangdong","518036","China","CN",{"type":44,"coordinates":45},"Point",[46,47],114.0683,22.54554,{"lat":47,"lon":46},[50],{"name":51,"role":31,"phone":52,"phoneExt":11,"email":53},"Zhen J Peng, Phd","+86 13076790039","Zhen-Peng@beijing-biotech.com",{"type":55,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100626588","phase-2-topical-ghk-cu-gel-for-acute-skin-wound-healing-100626588",false,"NCT07437586","Topical GHK-Cu Gel for Acute Skin Wound Healing","A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Split-Wound Study of Topical GHK-Cu (Copper(II)-Peptide Complex) Gel to Accelerate Re-Epithelialization of Standardized Acute Skin Wounds in Healthy Adults","CuHeal","Inclusion Criteria:\n\n* Age 18 to 55 years at screening.\n* Healthy adult as determined by medical history and limited physical examination.\n* Body mass index (BMI) 18.0 to 30.0 kg\u002Fm².\n* Willing and able to comply with study visits and daily product application for 14 days.\n* Willing to avoid applying non-study topical products (including medicated creams, retinoids, acids) to the wound area during the study period.\n* For participants of childbearing potential: negative pregnancy test at screening and agreement to use effective contraception through Day 21.\n\nExclusion Criteria:\n\n* Known allergy or sensitivity to copper, peptides, gel excipients, adhesives, or dressings used in the study.\n* History of abnormal wound healing, hypertrophic scarring, or keloid formation.\n* Clinically significant dermatologic disease near the intended wound site (e.g., eczema, psoriasis, active infection).\n* Diabetes mellitus, peripheral vascular disease, immunodeficiency, or other condition that may impair wound healing (investigator judgment).\n* Use of systemic corticosteroids, immunosuppressants, or cytotoxic medications within 30 days prior to Day 0.\n* Current smoker or nicotine use (including vaping) within the past 3 months.\n* Pregnant or breastfeeding.\n* Participation in another interventional clinical study within 30 days prior to screening.\n* Any condition that, in the investigator's opinion, would make participation unsafe or could interfere with study assessments.",true,"ALL","18 Years","55 Years",{"count":69,"type":70},60,"ESTIMATED","INTERVENTIONAL",[73],"PHASE2","This study will evaluate whether a topical gel containing GHK-Cu (a copper(II)-peptide complex) can safely speed up healing of small, standardized skin wounds in healthy adults compared with a matching vehicle gel.\n\nParticipants will receive two small punch-biopsy wounds on the upper arm; each wound will be randomly assigned to receive GHK-Cu gel or vehicle gel under identical dressings. Wounds will be photographed and assessed over 3 weeks, with a follow-up visit to evaluate scar quality.",[76],"Acute Standardized Cutaneous Wounds (Punch-biopsy Wounds)",[78,79,80,81,82,83,84,85],"GHK-Cu","copper peptide","Copper(II)-peptide complex","copper tripeptide-1","wound healing","re-epithelialization","skin repair","scar quality","2026-02-22",{"date":88,"type":89},"2026-02-27","ACTUAL",{"date":91,"type":89},"2026-02-02",{"date":93,"type":70},"2028-03-17",{"name":5,"class":6},1]